US · Healthcare · Medical Devices
EPS came in at -0.14 against a street estimate of -0.23 — a beat of 39.1%.
Analysts rate 10X Genomics Inc a buy (7 buy, 9 hold, 0 sell out of 16) with an average price target of $51.00.
CONFIDENT Q2 production at plan despite lower grades; 197k oz YTD tracking to 420-470k FY guidance. AISC raised to $2,000-2,100/oz due to peso strength and higher reagent costs, but margins robust at 46%. Strong FCF and shareholder returns continue. Q2 2026 All production concentrated in Morelos complex (Mexico). Media Luna North first ore late 2026 will add capacity. Analysts focused on cost drivers (peso vs. consumables), Media Luna North production milestones, and currency hedging strategy. Management emphasized reagent costs as primary lever, confirmed execution timeline, and outlined gradual hedging approach. 2026-08-07…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 13.62% |
| ARK Investment Management LLC | 8.99% |
| BlackRock Inc | 7.74% |
| Vanguard Portfolio Management, LLC | 5.31% |
| Quantinno Capital Management LP | 4.15% |
| Vanguard Capital Management, LLC | 4.04% |
| Amova Asset Management Americas, Inc | 3.92% |
| Sumitomo Mitsui Trust Group Inc | 3.22% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 10x GENOMICS, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue (Q2 2026): $151.0 million (down 12.7% vs Q2 2025's $172.9 million) - Products | 2026-08-07 |
| Results announced · Q3 2026 10X GENOMICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $151.0 million (down 13% vs. Q2 2025's $172.9 million); excluding | 2026-08-06 |
| Shareholder vote results · Q2 2026 10X GENOMICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 4, 2026 • Quorum achieved: 198,815,518 votes cast repr | 2026-06-08 |
| Quarterly report · Q1 2026 10X GENOMICS, INC. – Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue (Q1 2026): $150.8 million, down slightly from $154.9 million in | 2026-05-08 |
| Results announced · Q2 2026 10X GENOMICS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $150.8 million – down 3% year-over-year, but up 9% excluding $16. | 2026-05-07 |
| Proxy statement · Q2 2026 10X GENOMICS, INC. — PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal One: Election of Class I directors (three-year terms expirin | 2026-04-24 |
| Annual report FY2025 10X GENOMICS, INC. – FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue (FY 2025): $642.8 million, up 5% year-over-year from $610.8 m | 2026-02-13 |
| Results announced · Q1 2026 10X GENOMICS FY2025 EARNINGS SUMMARY HEADLINE NUMBERS • Full year 2025 revenue: $642.8 million (up 5% vs 2024's $610.8 million) • Excluding $44.1 mi | 2026-02-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for 10X Genomics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.